 |
|
Immune Thrombocytopenia Following  -Interferon Therapy in Patients With Cancer
Peter McLaughlin, MD;
Moshe Talpaz, MD;
Jorge R. Quesada, MD;
Abdus Saleem, MD;
Barthel Barlogie, MD;
Jordan U. Gutterman, MD
JAMA. 1985;254(10):1353-1354.
Abstract
Immune thrombocytopenia occurred in five patients with cancer receiving  -interferon. The median pretreatment platelet count was 217,000/cu mm, which fell to a median of 12,000/cu mm after a median of 25 days of interferon therapy. All had normal numbers of megakaryocytes, with dysplasia noted in three; all four who were tested had platelet-associated immunoglobulin. All had normalization of platelet counts with prednisone therapy. Four tolerated re-treatment with interferon, two with concurrent prednisone administration and two others following splenectomy. Immune thrombocytopenia should be considered in patients who become thrombocytopenic during interferon therapy.
(JAMA 1985;254:1353-1354)
Author Affiliations
From the Departments of Hematology (Drs McLaughlin and Barlogie) and Clinical Immunology and Biological Therapy (Drs Talpaz, Quesada, and Gutterman), The University of Texas M. D. Anderson Hospital and Tumor Institute; and the Department of Pathology, The Methodist Hospital and Baylor College of Medicine (Dr Saleem), Houston.
Footnotes
Reprint requests to Department of Hematology, University of Texas M. D. Anderson Hospital and Tumor Institute, 6723 Bertner Ave, Houston, TX 77030 (Dr McLaughlin).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Drugs Recently Associated With Lupus Syndromes
Fritzler
Lupus 1994;3:455-459.
ABSTRACT
Immune Thrombocytopenia After {alpha}-Interferon Therapy in Patients With Cancer
Abdi and Venner
JAMA 1986;255:1878-1879.
ABSTRACT
|
